Has Matthew McLean, MD received payments from drug or device companies?

Yes. Drug and device makers reported $113,479 in general payments to Matthew McLean, MD across 851 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew McLean, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew McLean, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew McLean, MD

Neurology · Mobile, ALNPI 1699086199

Payments from drug & device makers

$113,479in general payments, 2019–2025

Across 851 payments — averaging $133.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

UCB SA$99K
AbbVie$4K
UCB, Inc.$1K
Novartis$943
Lundbeck LLC$694
SK Life Science, Inc.$623
plus $7K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
UCB SA	6	$99,356
AbbVie(2 entities)	279	$3,671
UCB, Inc.	57	$1,170
Novartis	65	$943
Lundbeck LLC	42	$694
SK Life Science, Inc.	25	$623
Biogen	36	$560
Eisai Inc.	27	$547
Teva Pharmaceuticals USA, Inc.	33	$542
Lilly USA, LLC	38	$519
Pfizer	31	$397
Amgen(2 entities)	23	$396
Argenx US, Inc.	10	$368
Neurocrine Biosciences, Inc.	11	$231
Bristol Myers Squibb	15	$225
Sanofi	9	$219
Otsuka America Pharmaceutical, Inc.	10	$214
Medtronic(3 entities)	7	$201
Johnson & Johnson(2 entities)	11	$179
AstraZeneca(2 entities)	10	$176
Merz North America, Inc.	3	$162
Upsher-smith Laboratories LLC	9	$137
Supernus Pharmaceuticals, Inc.	7	$136
Tanabe Pharma America, Inc.	7	$134
Genentech USA, Inc.	2	$125
Merz Pharmaceuticals, LLC	6	$122
Sunovion Pharmaceuticals Inc.	1	$121
Catalyst Pharmaceuticals, Inc.	6	$111
Axsome Therapeutics, Inc.	5	$106
EMD Serono, Inc.	6	$100
Neurelis, Inc.	5	$99
Acadia Pharmaceuticals Inc	4	$99
Grifols USA, LLC	4	$80
Adamas Pharmaceuticals, Inc.	3	$68
Avanir Pharmaceuticals, Inc.	4	$67
Boston Scientific	2	$53
Acorda Therapeutics, Inc	2	$37
Scilex Pharmaceuticals Inc.	2	$33
Sanofi-aventis U.S. LLC	2	$31
Kedrion Biopharma, Inc.	2	$30
Route 92 Medical, Inc.	1	$29
Mallinckrodt Enterprises LLC	2	$28
Averitas Pharma Inc.	1	$26
Vanda Pharmaceuticals Inc.	1	$25
Amneal Pharmaceuticals LLC	2	$25
Alnylam Pharmaceuticals Inc.	1	$23
Molnlycke Health Care US, LLC	1	$21
Sonex Health, Inc.	1	$20
Kyowa Kirin, Inc.	1	$18
Octapharma USA, Inc.	1	$17
Mallinckrodt Hospital Products Inc.	1	$16
Tris Pharma Inc	1	$16
Tandem Diabetes Care, Inc.	1	$16
Inspiremd Ltd	1	$15
Neuronetics, Inc.	1	$15
Abbott	1	$14
Merck	1	$14
Arbor Pharmaceuticals, Inc.	1	$14
Assertio Therapeutics, Inc.	1	$13
MDD US Operations, LLC	1	$12

How this compares

$113,479 in reported general payments places this provider in the 85th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama →

Medicare billing

Part B allowed, 2024

$155,527

Medicare patients

412

Services billed

13,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Mobile

Daniel DeesMobile$894K
Hayden LongMobile$386K
William KilgoMobile$334K
John HintonMobile$270K
Charles MarkleMobile$212K
Bassam BassamMobile$197K
Dean NaritokuMobile$164K
Laura MintoMobile$92K
Steve CordinaMobile$75K
Thomas FosterMobile$51K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →